1255 GMT - Roche Holding struck an upbeat tone on its drug pipeline, but didn't deliver the guidance upgrade some expected, as it gave investors an update on its pharma business, RBC Capital Markets analysts say in a research note. The Swiss pharma group said Monday that it plans new studies for its breast-cancer drug candidate giredestrant across different treatment lines, combinations and settings of the disease. "While the breadth of the giredestrant program and broader pipeline provided encouragement around Roche's longer-term growth potential, the lack of midterm guidance update meant the event unlikely provided the incremental upside catalyst some investors had been hoping for," they add. Shares fall 1.2%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments